Copyright © 2026 VPM, all rights reserved.
PBS is a 501(c)(3) not-for-profit organization.
VPM News Morning Edition
NEXT UP: 9:00 AM

Thanks to our sponsors – Become a Sponsor

Antibiotic Use Ran High In Early Days Of COVID-19, Despite Viral Cause

Early on in the COVID-19 pandemic antibiotics were frequently prescribed to seriously ill patients, even though the disease is caused by a virus.
Win McNamee / Getty Images
Early on in the COVID-19 pandemic antibiotics were frequently prescribed to seriously ill patients, even though the disease is caused by a virus.

Doctors treating COVID-19 patients early in the pandemic often reached for antibiotics. But those drugs were not helpful in most cases, and overuse of antibiotics is a serious concern.

Several research groups, at Johns Hopkins, the University of Michigan and Bristol, England, have observed this trend. Now researchers at the Pew Charitable Trusts have weighed in with more data and put those findings in the context of long-term worries about the fate of antibiotics.

The Centers for Disease Control and Prevention estimates that nearly 3 million Americans a year get an infection that’s caused by a drug-resistant microbe. An estimated 35,000 Americans die from these hard-to-treat infections annually.

As a result, hospitals are supposed to follow rules to limit unnecessary use of antibiotics. Overuse of these medications hastens the development of new drug-resistant strains of bacteria.

But those rules haven’t been closely followed during the COVID-19 pandemic, particularly in its early days.

Here’s the scene doctors confronted. “You have a patient in front of you with this potentially lethal illness,” says Dr. Susan Swindells, an infectious diseases specialist at the University of Nebraska Medical Center. “They have a fever and a cough, and they have difficulty breathing. So, the overwhelming desire is to do whatever you can.”

In the absence of any effective drug therapy, that often meant reaching for antibiotics. Some patients got treated just in case that they actually had bacterial pneumonia, not COVID-19. Other times, doctors figured patients might have both COVID-19 and a bacterial infection. That double infection is fairly common among people hospitalized with influenza.

Back then, she says, “there was very little proven treatment for COVID so people were trying all kinds of things.”

“I think we are all aware of some overuse in COVID,” she said. And it’s hardly unique. “Lots of people with flu or even common colds get prescribed antibiotics when they don’t need them. It’s definitely an issue.”

Rachel Zetts at the Pew Charitable Trusts documents the use of antibiotics for COVID-19. The study in a group of about 5,000 hospitalized patients, chiefly in the Midwest, found that more than half were given antibiotics, even though most of them did not have bacterial infections.

Patients usually got the antibiotics right away, before doctors had time to run tests to rule out bacterial infections.

Doing that is “not inherently a bad practice,” says Zetts’ co-author, Dr. David Hyun at Pew. “It’s a necessary tool for providers to treat patients with suspected bacterial infections when they hit the doors of the hospital.”

Immediate treatment can save the life of someone with a sepsis, for example. That’s triggered by a bacterial infection.

But as the pandemic evolved, it became increasingly clear that antibiotics weren’t helping most COVID-19 patients.

Doctors usually discontinued therapy within a few days once they realized their patients wouldn’t benefit, their study found. Even so, this practice contributes to overuse of antibiotics and can gradually erode their potency. Hyun says hospitals had in recent years been compelled to adopt guidelines to rein in inappropriate antibiotic use.

“What we’re concerned is that the progresses we’ve seen in the last few years could reverse.”

The studies to date apply mostly to medial practices used in the first six months of the pandemic. Since then, doctors have had effective drugs to reach for, and have learned that their patients rarely get secondary bacterial infections.

Swindells says in her hospital, that’s reduced the impulse to reach for antibiotics.

“It’s still going on to a certain extent, but improved,” she says.

Those lessons have likely been learned in most places where COVID-19 is treated. The researchers at Pew are eager to see results from follow-up studies, to see if that is indeed the case.

You can contact NPR Science Correspondent Richard Harris at [email protected].

Copyright 2023 NPR. To see more, visit https://www.npr.org.

Award-winning journalist Richard Harris has reported on a wide range of topics in science, medicine and the environment since he joined NPR in 1986. In early 2014, his focus shifted from an emphasis on climate change and the environment to biomedical research.

Harris has traveled to all seven continents for NPR. His reports have originated from Timbuktu, the South Pole, the Galapagos Islands, Beijing during the SARS epidemic, the center of Greenland, the Amazon rain forest, the foot of Mt. Kilimanjaro (for a story about tuberculosis), and Japan to cover the nuclear aftermath of the 2011 tsunami.

In 2010, Harris' reporting revealed that the blown-out BP oil well in the Gulf of Mexico was spewing out far more oil than asserted in the official estimates. That revelation led the federal government to make a more realistic assessment of the extent of the spill.

Harris covered climate change for decades. He reported from the United Nations climate negotiations, starting with the Earth Summit in Rio de Janeiro in 1992, and including Kyoto in 1997 and Copenhagen in 2009. Harris was a major contributor to NPR's award-winning 2007-2008 "Climate Connections" series.

Over the course of his career, Harris has been the recipient of many prestigious awards. Those include the American Geophysical Union's 2013 Presidential Citation for Science and Society. He shared the 2009 National Academy of Sciences Communication Award and was a finalist again in 2011. In 2002, Harris was elected an honorary member of Sigma Xi, the scientific research society. Harris shared a 1995 Peabody Award for investigative reporting on NPR about the tobacco industry. Since 1988, the American Association for the Advancement of Science has honored Harris three times with its science journalism award.

Before joining NPR, Harris was a science writer for the San Francisco Examiner. From 1981 to 1983, Harris was a staff writer at The Tri-Valley Herald in Livermore, California, covering science, technology, and health issues related to the nuclear weapons lab in Livermore. He started his career as an AAAS Mass Media Science Fellow at the now-defunct Washington Star in DC.

Harris is co-founder of the Washington, DC, Area Science Writers Association, and is past president of the National Association of Science Writers. He serves on the board of the Council for the Advancement of Science Writing.

Harris' book Rigor Mortis was published in 2017. The book covers the biomedicine "reproducibility crisis" — many studies can't be reproduced in other labs, often due to lack of rigor, hence the book's title. Rigor Mortis was a finalist for the 2018 National Academy of Sciences/Keck Communication Award.

A California native, Harris returned to the University of California-Santa Cruz in 2012, to give a commencement address at Crown College, where he had given a valedictory address at his own graduation. He earned a bachelor's degree at the school in biology, with highest honors.

Related Stories